FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to genes operably linked in a vector, and can be used in medicine to relieve or treat pain. Disclosed is a pharmaceutical composition comprising an effective amount of two or more genes selected from a group consisting of a gene coding glutamate decarboxylase (GAD), a gene coding interleukin-10 (IL-10), and a gene coding a glial neurotrophic factor (GDNF). Genes in composition are in operable form in vector.
EFFECT: invention provides a high analgesic effect when introducing a combination of genes in a dose lower than when introducing the genes separately, and thus the usual side effects and toxicity can be reduced.
18 cl, 7 tbl, 7 ex, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2809246C2 |
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2811426C2 |
| COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| FUSED PROTEIN OF SHORT FORM OF CONE VIABILITY FACTOR OBTAINED FROM RODS, AND HYDROPHILIC PEPTIDE | 2017 |
|
RU2773368C2 |
| MULTIFUNCTIONAL MULTI-SPECIFIC MULTIMERIC BIOMOLECULAR POLYMER WITH PROLONGED IN VIVO EFFICIENCY | 2020 |
|
RU2805307C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
